Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)

Keros Therapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $400000.0 in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 20.48% year-over-year to $400000.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 22.78% YoY), and the FY2025 full-year result was $1.5 million, up 22.78% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $400000.0, up from $395000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $400000.0 in Q4 2025, with the low at $80000.0 in Q1 2021.
• Historically, Depreciation & Amortization (CF) has averaged $230250.0 across 5 years, with a median of $228500.0 in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 238.46% — and 2023, when it tumbled 37.99%.
• Keros Therapeutics' Depreciation & Amortization (CF) stood at $104000.0 in 2021, then advanced by 22.12% to $127000.0 in 2022, then soared by 94.49% to $247000.0 in 2023, then surged by 34.41% to $332000.0 in 2024, then grew by 20.48% to $400000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $400000.0 (Q4 2025), $395000.0 (Q3 2025), and $370000.0 (Q2 2025), per Business Quant data.